Extrawell Pharmaceutical Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 March 2024. The group expects to record a loss in the range between HKD 160 million and HKD 165 million, as compared to a profit for the year ended 31 March 2023. Such turnaround from profit to loss was primarily attributable to a non-cash item, resulted from the fair value change (loss) of the financial assets at fair value through profit or loss i.e. the Group's investments in convertible bonds, while a fair value change (gain) of the same non-cash item was recorded in the corresponding period last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.041 HKD | 0.00% |
|
+5.13% | +20.59% |
28/06 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
25/06 | Extrawell Pharmaceutical Warns of Swing to Loss in Fiscal Year 2024 | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.59% | 1.26Cr | |
+55.35% | 85TCr | |
+31.64% | 63TCr | |
-0.10% | 36TCr | |
+15.47% | 32TCr | |
+13.10% | 30TCr | |
+15.51% | 24TCr | |
+16.72% | 23TCr | |
+16.54% | 18TCr | |
+4.31% | 17TCr |
- Stock Market
- Equities
- 858 Stock
- News Extrawell Pharmaceutical Holdings Limited
- Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2024